The phase 1b breast cancer chemoprotection trial with ALRN-6924 in patients with p53-mutated breast cancer (NCT05622058) was terminated due to severe grade 4 neutropenia and alopecia, failing to meet the trial's main endpoints. This evidence concerns the gene TP53 and breast carcinoma.